Supernus Pharmaceuticals | SUPN - Loan Capital


Supernus Pharmaceuticals reported $400.38M in Loan Capital for its fiscal quarter ending in March of 2022.





Loan Capital Change Date
Abbott USD 29.64B 19.74B Mar/2026
ANI Pharmaceuticals USD 286M 5.84M Mar/2026
Aurora Cannabis CAD 33.2M 1.79M Dec/2025
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Canopy Growth CAD 224.99M 1.34M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Eisai JPY 134.78B 12M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Novo Nordisk DKK 119.17B 231M Mar/2026
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.62B 17.5M Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
United Therapeutics USD 100M 100M Jun/2024
Xeris Pharmaceuticals USD 221.22M 889K Mar/2026